Healthcare / Drug Manufacturers - Specialty & GenericNSE
$1416.10
-7.30 (-0.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-6.9M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.3B
P/E
34.7x
↑EV/EBITDA
N/A
•ROE
16.9%
↑Gross Margin
55.5%
↑Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
-4.2%
FCF / Net income
-0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.85B · net income $414.8M · FCF $-162.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.85B | $3.85B | $3.62B | $2.96B | $2.27B |
| Net Income | $414.8M | $414.8M | $424.2M | $364.4M | $307.2M |
| EBITDA | $868.6M | $868.6M | $764.7M | $612.1M | $537.5M |
| EPS | — | — | 42.02 | 37.90 | 30.43 |
| Gross Margin | 55.5% | 55.5% | 52.7% | 38.7% | 43.0% |
| Operating Margin | 15.2% | 15.2% | 17.1% | 17.0% | 18.9% |
| Net Margin | 10.8% | 10.8% | 11.7% | 12.3% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.60 | 0.60 | 0.70 | 0.09 | 0.17 |
| Current Ratio | 3.10 | 3.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-162.0M | $-162.0M | $-6.9M | $193.1M | $51.7M |
| Returns | |||||
| ROE | 16.9% | 16.9% | 21.5% | 23.2% | 25.0% |
| Valuation | |||||
| P/E | 34.67 | 34.67 | 45.14 | 36.41 | 23.00 |
| EV/EBITDA | — | — | 24.92 | 22.53 | 13.17 |
| P/B | — | — | 9.71 | 8.87 | 5.75 |
| Growth & Yield | |||||
| Revenue Growth | 6.2% | 6.2% | 22.5% | 30.2% | — |
| EPS Growth | — | — | 10.9% | 24.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.4%
Start / end P/E
n/dx → n/dx
EPS bridge
42.02 → n/d
Residual
-24.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.